CDKN2A and cancer: Based on the study of cancer cell lines, loss of pRb function by gene deletion or mutation, amplification of CCNE1, and high p16 expression were often associated with resistance to the drug (Dean et al, 2010; Ertel et al, 2010; Asghar et al, 2015).